Showing 8181-8190 of 10256 results for "".
- Garnier Debuts Product Impact Ranking Across Hair Care Rangehttps://practicaldermatology.com/news/garnier-debuts-product-impact-ranking-across-hair-care-range/2461455/Garnier is launching a digital labeling system that ranks its hair care products versus other L'Oreal Group Products based on 14 environmental factors. Product Impact Labelling ranks each product from A to E, with "A" indicating the 10% of L'Oreal Group Products in the
- AD News: Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapyhttps://practicaldermatology.com/news/ad-news-alphyn-biologics-completes-first-cohort-of-phase2a-clinical-trial-of-topical-therapy-1/2461432/Alphyn Biologics completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mil
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month-1/2461411/November is Hyperhidrosis Awareness Month and the
- Skin Microbiome Linked to GVHD Following Stem Cell Transplant in Leukemiahttps://practicaldermatology.com/news/skin-microbiome-linked-to-gvhd-following-stem-cell-transplant-in-leukemia/2461385/Organ damage occurs in up to 70 percent of patients in the first few months following stem cell transplant, but the precise reasons for this potentially life-threatening reaction haven’t been fully understood. Now, researchers led by Georg Stary from the Department of Dermatology at MedUni
- NEA Introduces New “Focus on Eczema” Campaign for Eczema Awareness Month 2022https://practicaldermatology.com/news/nea-introduces-new-focus-on-eczema-campaign/2461367/The National Eczema Association (NEA) is rolling out its annual
- Galderma, NBCF Partner to Launch Campaign Elevating Skin Stories of Breast Cancer Survivorshttps://practicaldermatology.com/news/galderma-nbcf-partner-to-launch-campaign-elevating-skin-stories-of-breast-cancer-survivors/2461366/Galderma is continuing its partnership with National Breast Cancer Foundation Inc. (NBCF) with a new campaign that elevates the skin stories of breast cancer survivors. Galderma is featuring the personal stories and treatment journeys of breast cancer survivors who received Re
- Game On: IFPA Launches the “Explore Psoriatic Disease Together” Campaign to Build the IFPA Island on Animal Crossing: New Horizonshttps://practicaldermatology.com/news/game-on-ifpa-launches-the-explore-psoriatic-disease-together-campaign-to-build-the-ifpa-island-on-animal-crossing-new-horizons/2461328/The International Federation of Psoriatic Disease Associations (IFPA) is launching a campaign to build the IFPA Island on the Nintendo video game, Animal Crossing: New Horizons. This new campaign is called “Explore Psoriatic Disease Together” and calls on the psoriatic disea
- Arcutis Rolls Out New Psoriasis Public Awareness Campaignhttps://practicaldermatology.com/news/arcutis-rolls-out-new-psoriasis-public-awareness-campaign/2461321/Arcutis Biotherapeutics, Inc. is launching an educational campaign designed to raise awareness about the physical and emotional impact of plaque psoriasis and empower those living with the disease to have open, honest conversations with their healthcare providers, family, and friends.
- CeraVe, Top Derms, and Skincare Enthusiasts Partner to Teach Consumers to #CleanseLikeaDermhttps://practicaldermatology.com/news/cerave-top-derms-and-skincare-enthusiasts-partner-to-teach-consumers-to-cleanselikeaderm/2461283/CeraVe is teaming up with board-certified dermatologists and two of the biggest dermatologist influencers on social media today – Dr. Dustin Portela (@208skindoc) and Dr. Michelle Henry (@drmichellehenry) – to host a global livestreamed event with skincare enthusiast and content creat
- Zoryve from Arcutis Approved for Plaque Psoriasishttps://practicaldermatology.com/news/zoryve-from-arcutis-approved-for-plaque-psoriasis/2461282/FDA has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhib